The development of the prodrug oral Pemetrexed to improve the QOL of non-small cell lung cancer patients.

○Ayagi Yamoto

[26P2-pm1-066S] The development of the prodrug oral Pemetrexed to improve the QOL of non-small cell lung cancer patients.

○Ayagi Yamoto¹, Shinji Yamamoto¹, Hideo Kobata¹, Takumi Nakata¹, Tomohirm Maegawa¹, Hikaru Nakamura¹, Hyuji Ota¹, Tetutaro Kimachi², Kasumi Miyoshi², Ayuko Takumi², Sumio Mazuno¹, Manabu Kitakoji¹, Katuyuki Takahashi¹, Toru Otori¹, Kenji Matuyama³ (1. Faculty of Pharmacy, Kindai Univ., 2. School of Pharmacy, Mukogawa Weman Univ., 3. Aioi City Nursing College.)

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.

Presentation information

[26P2-pm1] Clinical Pharmacy 1/Social pharmacy 1

[26P2-pm1-066S] The development of the prodrug oral Pemetrexed to improve the QOL of non-small cell lung cancer patients.

Password